Top ▲

Axial spondyloarthritis

Disease ID:1256
Name:Axial spondyloarthritis
Associated with:0 target
1 immuno-relevant ligand
Axial SpA
Axial spondyloarthritis is an umbrella term that covers a diverse family of diseases that share clinical and genetic features. Diseases encompassed by this term are all chronic autoinflammatory diseases that cause inflammation and pain in the joints of the spine and/or sacroiliac joints (the axial sleleton), such as ankylosing spondylitis.


No target related data available for Axial spondyloarthritis


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
certolizumab pegol
Immuno Disease Comments: Approved drug for axial spondyloarthritis (EMA 2009)
Clinical Use: Used to treat rheumatoid arthritis (RA) and Crohn's disease [1]. May also have some effect in related conditions such as axial spondyloarthritis [3]. The EMA granted Europe-wide approval for the use of this drug in patients with RA (moderate to severe, active disease and severe, active and progressive disease), axial spondyloarthritis and psoriatic arthritis in 2009. FDA approval was expanded to include treatment of moderate-to-severe plaque psoriasis, in June 2018. | View clinical data
Bioactivity Comments: Certolizumab pegol neutralises soluble TNFα in vitro, with an IC90 of 3ng/ml [2], neutralises the effects mediated by membrane bound TNFα, and inhibits production of IL-1β in monocytes stimulated with LPS. | View biological activity


Show »

1. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA. (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford), 41 (10): 1133-7. [PMID:12364632]

2. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T. (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis, 13 (11): 1323-32. [PMID:17636564]

3. Song IH, Rudwaleit M. (2013) Certolizumab pegol in axial spondyloarthritis. Expert Rev Clin Immunol, 9 (12): 1161-72. [PMID:24215406]